Cargando…
Efficacy of orthoMTA, retroMTA and ferric sulphate as pulpotomy agents in primary molars: a randomized clinical trial
PURPOSE: The purpose of this study is to evaluate the clinical and radiographic success rates of RetroMTA, OrthoMTA, and ferric sulfate as pulpotomy agents in primary molars. MATERIALS AND METHODS: Ninety-six primary second molars from 32 children aged 5 to 9 years were enrolled in this study. The t...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Istanbul University Faculty of Dentistry
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622155/ https://www.ncbi.nlm.nih.gov/pubmed/37929220 http://dx.doi.org/10.26650/eor.2023950004 |
_version_ | 1785130480284205056 |
---|---|
author | Yilmaz, Sıla Keles, Sultan |
author_facet | Yilmaz, Sıla Keles, Sultan |
author_sort | Yilmaz, Sıla |
collection | PubMed |
description | PURPOSE: The purpose of this study is to evaluate the clinical and radiographic success rates of RetroMTA, OrthoMTA, and ferric sulfate as pulpotomy agents in primary molars. MATERIALS AND METHODS: Ninety-six primary second molars from 32 children aged 5 to 9 years were enrolled in this study. The teeth were randomly divided into three groups based on the pulpotomy agent used: O-MTA, R-MTA, and FS. Clinical and radiographic follow-up examinations were conducted at 3, 6, 9, and 18 months postoperatively. RESULTS: At the end of the study period, 84 teeth were evaluated. The clinical success rates were 75% for FS, 96.4% for O-MTA, and 92.8% for R-MTA groups. In the radiographic analysis, the success rates at the 18-month follow-up period were 50% for FS, 85.8% for O-MTA, and 82.2% for R-MTA groups. According to the Chi-square test and Kaplan-Meier survival analysis, there was a statistically significant difference among the success rates and survival probabilities of the groups (p<0.05). CONCLUSION: OrthoMTA and RetroMTA demonstrated better treatment outcomes for pulpotomy of primary second molars than ferric sulfate at the 18-month follow-up period. |
format | Online Article Text |
id | pubmed-10622155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Istanbul University Faculty of Dentistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-106221552023-11-03 Efficacy of orthoMTA, retroMTA and ferric sulphate as pulpotomy agents in primary molars: a randomized clinical trial Yilmaz, Sıla Keles, Sultan Eur Oral Res Articles PURPOSE: The purpose of this study is to evaluate the clinical and radiographic success rates of RetroMTA, OrthoMTA, and ferric sulfate as pulpotomy agents in primary molars. MATERIALS AND METHODS: Ninety-six primary second molars from 32 children aged 5 to 9 years were enrolled in this study. The teeth were randomly divided into three groups based on the pulpotomy agent used: O-MTA, R-MTA, and FS. Clinical and radiographic follow-up examinations were conducted at 3, 6, 9, and 18 months postoperatively. RESULTS: At the end of the study period, 84 teeth were evaluated. The clinical success rates were 75% for FS, 96.4% for O-MTA, and 92.8% for R-MTA groups. In the radiographic analysis, the success rates at the 18-month follow-up period were 50% for FS, 85.8% for O-MTA, and 82.2% for R-MTA groups. According to the Chi-square test and Kaplan-Meier survival analysis, there was a statistically significant difference among the success rates and survival probabilities of the groups (p<0.05). CONCLUSION: OrthoMTA and RetroMTA demonstrated better treatment outcomes for pulpotomy of primary second molars than ferric sulfate at the 18-month follow-up period. Istanbul University Faculty of Dentistry 2023-09-06 2023-09-06 /pmc/articles/PMC10622155/ /pubmed/37929220 http://dx.doi.org/10.26650/eor.2023950004 Text en Copyright © 2023 European Oral Research https://creativecommons.org/licenses/by-nc-nd/4.0/This article is licensed under Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license ( (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the journal endorses its use. The material cannot be used for commercial purposes. If the user remixes, transforms, or builds upon the material, he/she may not distribute the modified material. No warranties are given. The license may not give the user all of the permissions necessary for his/her intended use. For example, other rights such as publicity, privacy, or moral rights may limit how the material can be used. |
spellingShingle | Articles Yilmaz, Sıla Keles, Sultan Efficacy of orthoMTA, retroMTA and ferric sulphate as pulpotomy agents in primary molars: a randomized clinical trial |
title | Efficacy of orthoMTA, retroMTA and ferric sulphate as pulpotomy agents in primary molars: a randomized clinical trial |
title_full | Efficacy of orthoMTA, retroMTA and ferric sulphate as pulpotomy agents in primary molars: a randomized clinical trial |
title_fullStr | Efficacy of orthoMTA, retroMTA and ferric sulphate as pulpotomy agents in primary molars: a randomized clinical trial |
title_full_unstemmed | Efficacy of orthoMTA, retroMTA and ferric sulphate as pulpotomy agents in primary molars: a randomized clinical trial |
title_short | Efficacy of orthoMTA, retroMTA and ferric sulphate as pulpotomy agents in primary molars: a randomized clinical trial |
title_sort | efficacy of orthomta, retromta and ferric sulphate as pulpotomy agents in primary molars: a randomized clinical trial |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622155/ https://www.ncbi.nlm.nih.gov/pubmed/37929220 http://dx.doi.org/10.26650/eor.2023950004 |
work_keys_str_mv | AT yilmazsıla efficacyoforthomtaretromtaandferricsulphateaspulpotomyagentsinprimarymolarsarandomizedclinicaltrial AT kelessultan efficacyoforthomtaretromtaandferricsulphateaspulpotomyagentsinprimarymolarsarandomizedclinicaltrial |